Observational studyPloS one2022

Real-world impact of primary immune thrombocytopenia and treatment with thrombopoietin receptor agonists on quality of life based on patient-reported experience: Results from a questionnaire conducted in Switzerland, Austria, and Belgium.

Alicia Rovó et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.